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One of the major obstacles to obtaining a complete structural and functional understanding of proteins
encoded by the Mycobacterium tuberculosis (Mtb) pathogen is due to signiﬁcant diﬃculties in producing
recombinant mycobacterial proteins. Recent advances that have utilised the closely related
Mycobacterium smegmatis species as a native host have been eﬀective. Here we have developed
a method for the rapid screening of both protein production and puriﬁcation strategies of mycobacterial
proteins in whole M. smegmatis cells following green ﬂuorescent protein (GFP) ﬂuorescence as an
indicator. We have adapted the inducible T7-promoter based pYUB1062 shuttle vector by the addition of
a tobacco etch virus (TEV) cleavable C-terminal GFP enabling the target protein to be produced as
a GFP-fusion with a poly-histidine tag for aﬃnity puriﬁcation. We illustrate the advantages of
a ﬂuorescent monitoring approach with the production and puriﬁcation of the mycobacterial N-
acetylglucosamine-6-phosphate deacetylase (NagA)-GFP fusion protein. The GFP system described here
will accelerate the production of mycobacterial proteins that can be used to understand the molecular
mechanisms of Mtb proteins and facilitate drug discovery eﬀorts.Introduction
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb),
is now the leading cause of human mortality from an infectious
agent. In 2016, 1.7 million deaths and 10.4 million new cases of
TB were reported by the WHO.1 Whilst TB can be treated, the
current drug-regimen is complicated and of long-duration
requiring a combination of the four rst-line drugs over
a period of 6–9 months.2 Recently, there has been an increase in
the emergence of numerous drug-resistant strains which
further complicates the regimen, prolongs treatment and is
more expensive to administer. Extensively-drug resistant (XDR-
TB) strains of TB have now been reported in 123 countries and
there are oen no therapeutic agents to successfully treat these
TB cases.1 Therefore, an increased knowledge of biochemical
pathways employed by theMtb pathogen is urgently required in
order to develop new anti-tubercular agents with novel modes of
action to reduce the global health threat from TB.
An important prerequisite towards obtaining a complete
biochemical understanding of the Mtb pathogen for improved
diagnostics and therapeutics is the ability to produce recombi-
nant proteins for structural and functional studies. However, theCoventry, CV4 7AL, UK. E-mail: e.fullam@
tion (ESI) available. See DOI:
hemistry 2018production of high quality recombinant Mtb proteins in suﬃ-
cient quantity has proved to be particularly challenging and has
hampered progress in this area.3 Escherichia coli is one of the
most commonly used bacterial host expression systems for the
overexpression of recombinant proteins but oen results in the
production of insoluble inclusion bodies which is a major
bottleneck for structural and functional studies.4,5 A number of
studies have shown that the ability to produce soluble proteins
from Mtb in E. coli that are correctly folded and active is partic-
ularly challenging3,6 and this has been partially attributed to the
diﬀerent G + C content between E. coli andMtb which have G + C
contents of 51%7 and of 66%8 respectively, although other factors
may also contribute.
Given the limitations of E. coli as a host expression system
for mycobacterial proteins a number of diﬀerent systems have
been explored for Mtb protein production. These include the
use of Gram-negative Pseudomonas putida,9 Gram-positive
Streptomyces lividans10 and Rhodococcus jostii,11 the yeast
Saccharomyces cerevisiae12 as well as the baculovirus expression
system in insect cells,13 although these alternative host-systems
are not routinely used. It is generally considered that intrinsic
diﬃculties in producing soluble protein can be overcome
through the use of a host expression system that is more closely
related to the target protein and therefore Mycobacterium
smegmatis, which is a faster-growing mycobacterium and oen
used as a non-pathogenic model of Mtb, has been successfully
utilised as a host system for the expression of a number ofRSC Adv., 2018, 8, 33087–33095 | 33087
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View Article Onlinerecombinant Mtb and mycobacterial proteins.3,6 To date, 55
structures of Mtb proteins expressed in M. smegmatis are now
deposited in the protein data bank indicating the importance of
this host-expression system for recombinant mycobacterial
protein production.14 The advantages of using M. smegmatis as
an expression system are numerous. The constitutive produc-
tion of mycobacterial chaperones is likely to assist in the correct
folding of theMtb recombinant protein and is an approach that
has been used successfully as a strategy in E. coli whereby
mycobacterial chaperones are co-expressed with the target Mtb
protein to obtain soluble proteins.15,16 Furthermore, the avail-
ability of mycobacterial specic metabolites, ligands and/or
binding protein/s may lead to the production of correctly fol-
ded active protein.17 An example is the successful production of
the Mtb F420-binding protein that could only be produced in an
M. smegmatis host expression system and is believed to be due
to the absence of the required F420 cofactor in E. coli.18
Furthermore, we have recently shown that the expression
system can play a key role in the selection of the incorporated
cofactor. Production of the mycobacterial N-acetylglucosamine-
6-phosphate deacetylase (NagA) enzyme results in the
incorporation of diﬀerent metal ions depending on the host
expression system with more stable, active protein produced in
the M. smegmatis host.19
The vectors and strains that are currently available for the
overexpression of proteins in M. smegmatis are not as varied or
developed as the tools that are well established for E. coli.
Recent progress in this area, however, has led to the adaption of
the T7 promoter-based vector system, a commonly used system
for overexpression of proteins in E. coli,20 for use in M. smeg-
matis by the introduction of the RNA polymerase from the T7
bacteriophage and the generation of the M. smegmatis mc24517
host strain.21 An alternative host is the M. smegmatis groEL1DC
strain that has a mutated C-terminal GroEL1 chaperone.22 This
strain has also been developed to enable eﬃcient purication of
poly-histidine-tagged mycobacterial proteins by mutating the
histidine rich region of the GroEL1 chaperone to reduce its co-
purication along with the target-protein during immobilised
metal aﬃnity chromatography (IMAC) and has been used for
the successful expression of mycobacterial proteins.22,23 The two
main vector systems for recombinant protein expression in M.
smegmatis are an acetamidase promoter based system and
include the pSD24 and pMyNT25 series of expression vectors and
the T7 promoter-based vectors that include the shuttle vectors
pYUB1049 and pYUB1062,21 a Gateway cloning system
pDESTsmg6 and the pYUBDUET26 vector for the co-expression of
proteins. Although the M. smegmatis expression host has
improved the production of recombinant mycobacterial
proteins it does not always result in correctly folded proteins.
Therefore, we wanted to develop a mycobacterial expression
vector using GFP as an indicator to rapidly monitor protein
production in M. smegmatis. This is an approach that has been
used successfully in E. coli where a C-terminal GFP tag has been
used as a reporter for the production of correctly folded globular
and membrane proteins.27–29 A direct correlation is observed
between the GFP uorescence and the production of correctly
folded protein that is fused upstream and the reported output33088 | RSC Adv., 2018, 8, 33087–33095sensitive to protein misfolding and aggregation, with no
detectable uorescence observed when the protein is expressed
in inclusion bodies.
In this study we demonstrate a widely applicable, eﬃcient
protocol using GFP as a tool for monitoring the overexpression
of mycobacterial proteins inM. smegmatis. We have adapted the
inducible T7-promoter based pYUB1062 vector and incorpo-
rated a cleavable C-terminal GFP-His6 reporter tag to produce
the target protein as a GFP-fusion. We show that protein
production can be eﬃciently monitored by GFP uorescence in
situ in whole M. smegmatis cells. The GFP-fusion-tag does not
hinder protein production and can be used to monitor puri-
cation strategies by simple procedures that include in-gel uo-
rescence. Taken together, our ndings demonstrate that GFP is
suitable for widespread use as an excellent tool for the rapid
production of mycobacterial proteins in an M. smegmatis host.
Materials and methods
Materials and reagents
All chemicals and reagents were purchased from Sigma-Aldrich,
unless specied. PCR and restriction enzymes were obtained
from New England Biolabs.
Bacterial strains and media
E. coli strain Top10 (Invitrogen) was used for the cloning of
expression constructs. Transformations were selected using
Luria Bertani (LB) medium containing the appropriate antibi-
otics. M. smegmatis mc24517 strain (a gi from Professor W. R.
Jacobs) was used for protein expression and was maintained in
LB medium supplemented with 0.2% glycerol and 0.05%
Tween-80 with the addition of the appropriate antibiotics.
Construction of pYUB1062-GFP
The DNA fragment encoding the tobaccoetch virus (TEV)
protease cleavage site and GFP fragment from the plasmid
pWaldoD was amplied by PCR using the primers listed in
Table 1. The PCR product was digested with the HindIII
restriction enzyme and ligated into the HindIII site of the
digested pYUB1062 vector (a gi from Professor W. R. Jacobs).
The correct orientation of the TEV-GFP insert was conrmed by
DNA sequencing. Subsequently, targeted site-directed muta-
genesis was performed to maintain a single HindIII site within
the multiple-cloning site using the primers listed in Table 1 and
remove the second HindIII, incorporated during the rst
cloning step, with Phusion Polymerase and the PCR cycle (98 C,
30 s; 25 cycles of 98 C, 10 s; 60 C, 30 s; 72 C, 4min; followed by
5 min at 72 C), followed by digestion with DpnI. Plasmid
sequences were veried by DNA sequencing (GATC) and
removal of the additional HindIII site conrmed. This resulted
in the formation of the resulting expression vector designated
pYUB1062-GFP.
Cloning of nagA
The full-length N-acetylglucosamine-6-phosphate deacetylase
(nagA) gene from Mycobacterium smegmatis was amplied byThis journal is © The Royal Society of Chemistry 2018
Table 1 Oligonucleotides used in this study. Restriction recognition sites are in italics. Codon encoding the amino acid mutation is indicated in
bold type
Name Use Sequence (50–30)
GFP_pYUB1062_F Clone GFP into pYUB1062 AAAAAAAAGCTTCCGAAAACCTGTACTTCCAGGGTC
GFP_pYUB1062_R Clone GFP into pYUB1062 AAAAAAAAGCTTTTTGTAGAGCTCATCCATGC
pYUB_GFP_SDM_F Mutate HindIII site TGAGCTCTACAAAAAGGGTGCGGCCGCACTCGAGC
pYUB_GFP_SDM_R Mutate HindIII site GCTCGAGTGCGGCCGCACCCTTTTTGTAGAGCTCA
NagA_pYUBGFP_F Clone nagA into pYUB1062-GFP CACCAACATATGCTGCTGACCGCCGACACCGTG
NagA_pYUBGFP_R Clone nagA into pYUB1062-GFP TATAAAAAGCTTCCACCGTGTGCGCCGCGCCG
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View Article Onlinepolymerase chain reaction from theMSnagA_pYUB1062 vector.19
The primer sequences used are listed in Table 1. The PCR
products were digested with NdeI and HindIII and ligated into
the pYUB1062-GFP vector digested with the same restriction
enzymes, resulting in the construct nagA_pYUB1062-GFP.
Plasmid sequences were veried by DNA sequencing (GATC)
and used for protein expression.
Growth curves
Growth of M. smegmatis in the presence/absence of pYUB1062,
pYUB1062-GFP and nagA_pYUB1062-GFP were carried out in
a 96-well microtiter plate (Falcon: black with clear bottom). The
optical density at 600 nm (OD600) and the GFP uorescence at
lex 485 nm lem 535 nm were monitored simultaneously every
20 min for 100 hours at 37 C (orbital shaking 430 rpm, Tecan
Innite F200, gain 35). Cultures were grown in LB medium
supplemented with 0.05% Tween-80, 0.2% glycerol with addi-
tion of the appropriate antibiotics. Induction of protein was at
OD600 of 0.6 by the addition of acetamide (0–0.4%). All experi-
ments were carried out in triplicate. The curves were tted to the
data points using the Lowess t in GraphPad Prism V7.
Protein expression of GFP and NagA-GFP in Mycobacterium
smegmatis
M. smegmatismc24517 electrocompetent cells were transformed
with either the pYUB1062-GFP or the nagA_pYUB1062-GFP
construct and grown at 37 C to an OD600 of 0.6 in LB medium
supplemented with 0.05% Tween-80, 0.2% glycerol, 25 mg mL1
kanamycin and 100 mg mL1 hygromycin. Protein production
was induced with 0.2% acetamide and the cultures were grown
at 37 C for an additional 20 hours with shaking (180 rpm). Prior
to harvesting the cells, 1 mL of the culture was removed,
centrifuged (10 min, 4 C), the pellet resuspended in 100 mL PBS
and the uorescence monitored at lex 485 nm lem 535 nm
(Tecan Innite F200, gain 35). The cells were then centrifuged
(5000g, 30 min 4 C) and the pellets frozen at 80 C until
further use.
Protein purication
The cells were resuspended in lysis buﬀer (20 mM Tris, 300 mM
NaCl, 10% glycerol pH 8.0 (buﬀer A)) supplemented with 0.1%
Triton-X 100, Complete Protease Inhibitor Cocktail (Pierce),
5 mM MgCl2, 2 mg DNase and 20 mg lysozyme. The resus-
pended pellet was incubated at 37 C for 10 min and the pellet
passed through a Cell Disruptor at 25 kpsi at 4 C (ConstantThis journal is © The Royal Society of Chemistry 2018Systems). Following centrifugation (27 000g, 40 min, 4 C) the
supernatant was ltered (0.45 mm pore size) before loading onto
a pre-equilibrated immobilised metal aﬃnity chromatography
(IMAC) resin.
GFP protein purication
The GFP protein was puried by loading onto a pre-equilibrated
HisPur Ni2+-aﬃnity resin (Thermo Scientic). The column was
washed with buﬀer A (5 column volumes) and the recombinant
GFP protein was eluted from the Ni2+-resin with increasing
concentrations of imidazole. Fractions containing the puried
GFP protein as determined by SDS-PAGE were dialysed at 4 C
for 12 hours against buﬀer A and the concentration of the
protein determined.
NagA protein purication
The lysate containing the NagA-GFP-His6 protein (69 kDa) was
loaded onto a pre-equilibrated HisPur Co2+-aﬃnity resin
(Thermo Scientic). The column was washed with buﬀer A (5
column volumes) and the recombinant NagA-GFP-His6 protein
was eluted from the Co2+-resin with increasing concentrations
of imidazole. Fractions containing the NagA-GFP-His6 protein
were dialysed at 4 C for 12 hours against 20 mM Tris–HCl,
100mMNaCl, 10% glycerol pH 8.0 (buﬀer B) at 4 C for 12 hours
and applied to a HiTrap Q-column (1 mL, GE Healthcare Life
Sciences) pre-equilibrated with buﬀer B and eluted with NaCl
(0.1–1 M). Fractions containing NagA-GFP-His6 were pooled and
puried further using size exclusion chromatography. Gel
ltration experiments were carried out on a Superdex 200 16/60
column (GE Healthcare) using 20 mM Bis-Tris, 300 mM NaCl,
10% glycerol pH 8.0 (buﬀer C). To remove the C-terminal GFP-
His6-tag, fractions containing puried NagA-GFP-His6, as
determined by SDS-PAGE, were pooled and incubated for 16
hours at 4 C in the presence of the histidine-tagged super TEV
protease (1 : 30 ratio) and loaded onto a pre-equilibrated Ni2+-
aﬃnity resin. The column was washed with buﬀer C (5 column
volumes) and the cleaved NagA protein (40 kDa) was eluted
from the Ni2+ resin. The NagA protein was pooled, 0.03% DDM
and 1 mM DTT were added and the protein concentrated to
5–10mgmL1 (Vivaspin 2, GEHealthcare) and stored at80 C.
In-gel uorescence readings
Samples for SDS-PAGE were mixed in a 1 : 1 ratio with loading
buﬀer (100 mM Tris, pH 6.8, 4% w/v SDS, 0.2% w/v bromo-
phenol blue, 10% v/v b-mercaptoethanol and 20% v/v glycerol)RSC Adv., 2018, 8, 33087–33095 | 33089
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View Article Onlineand samples (20 mL) loaded directly onto the gel (Any kD™
Mini-PROTEAN TGX Precast protein gels, Bio-Rad) without
heating. Following SDS-PAGE the in-gel uorescence was
imaged immediately using lex 460 nm and the detection lter
510DF10 GFP, with an exposure time of 0.25 s (ImageQuant LAS
4000). The exposure time was selected to ensure that the
brightest bands were not saturated. The gels were then stained
with InstantBlue™ Coomassie Protein stain.Circular dichroism (CD) analysis
Puried proteins (0.3 mg mL1) were dialysed in 20 mM Tris,
100 mM NaCl, 10% glycerol pH 8.0 buﬀer, transferred into
a 1 mm path length quartz cuvette and analysed on Jasco J-810
DC spectrometer from 198–260 nm. Spectra were acquired in
triplicate and averaged aer subtraction of the buﬀer
background.NagA assay
The activity of both NagA and NagA-GFP-His6 enzymes was
measured at 37 C in an end point assay by following the
production of the uorescent product formed with uoresc-
amine and primary amines at lex 340 nm lem 460 nm. The
reaction was carried out in a 96-well microtiter plate in 20 mM
Bis–Tris, 300 mM NaCl, 10% glycerol pH 7.0 in a total reaction
volume of 50 mL. The reaction was initiated by the addition of N-
acetylglucosamine-6-phosphate (GlcNAc6P) (Carbosynth) and
terminated by the addition of 50 mL 0.4 M borate buﬀer pH 10,
40 mL 5mM uorescamine (Carbosynth) and 50 mL DMF and the
production of uorescence was monitored (Tecan Innite
M200, constant gain). The production of free amine wasFig. 1 Construction of pYUB1062-GFP vector. (a) Schematic of the pWa
TEV-DNA fragment into the pYUB1062 vector. The second HindIII sit
arrangement of the pYUB1062-GFP vector.
33090 | RSC Adv., 2018, 8, 33087–33095quantied with a glucosamine standard. The kinetic parame-
ters Km and Vmax were determined by tting the velocity versus
substrate concentration to the Michaelis-Menten equation
using non-linear regression analysis (GraphPad Prism, V7). All
measurements were performed in triplicate.Results and discussion
Construction of the M. smegmatis pYUB1062-GFP expression
vector
In order to construct a uorescent indicator system to monitor
recombinant protein expression in M. smegmatis mc24517 we
selected the pYUB1062 shuttle vector,21 which can replicate in
both E. coli and M. smegmatis, for incorporation of a C-terminal
fused GFP-His6-tag to the target protein. The pYUB1062 vector
contains a T7 promoter for inducible protein expression with
either acetamide or IPTG, and a multiple-cloning site introduced
from the pET30a plasmid and allows for either an N- and/or C-
terminal His6-tag/s for purication depending on the selected
cloning strategy (Fig. 1). The pWaldo vector, which contains a C-
terminal GFP-His8 tag that can be cleaved by the tobacco etch
virus (TEV) protease (Fig. 1(a)), has been used extensively to
monitor the production of both cytosolic andmembrane proteins
in E. coli.27–29 In order to convert the pYUB1062 vector (Fig. 1(b))
we amplied the TEV-GFP DNA fragment from the pWaldo vector
and inserted this fragment into the HindIII site of the pYUB1062
vector that following translation, is in-frame with the trans-
lational start-site (Fig. 1(c)) and encodes for a C-terminal His6
aﬃnity-tag. The introduction of this fragment resulted in the
generation of an additional HindIII site into the backbone of the
vector (Fig. 1(c)), which was subsequently removed by usingldoD vector. (b) Schematic of the pYUB1062 vector. (c) Insertion of the
e that is introduced is highlighted in red dashed lines. (d) The ﬁnal
This journal is © The Royal Society of Chemistry 2018
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View Article Onlinetargeted site-directed mutagenesis. The resultant plasmid is
shown in Fig. 1(d) and is designated pYUB1062-GFP.Production and purication of GFP from M. smegmatis
mc24517
To test whether we were able to express and monitor the
production of GFP in situ we rst overexpressed GFP from the
pYUB1062-GFP vector in M. smegmatis mc24517. M. smegmatis
mc24517 strains, in the presence or absence of pYUB1062 or theFig. 2 Growth rates and green ﬂuorescent protein (GFP) ﬂuorescence
mc24517. (b) GFP ﬂuorescence of M. smegmatis mc24517. (c) Growth c
ﬂuorescence of M. smegmatismc24517 transformed with pYUB1062. (e)
GFP. (f) GFP ﬂuorescence ofM. smegmatismc24517 transformed with pY
– 0.1%, blue – 0.2%, black – 0.4%. The dashed black line represents a m
This journal is © The Royal Society of Chemistry 2018newly constructed pYUB1062-GFP, were grown to an OD600 of
0.6 in LB expression media followed by induction with acet-
amide (0–0.4%). The growth rate and the uorescence output
following induction were measured simultaneously in whole
cells (Fig. 2). The induction time point is dened as t ¼ 0.
Compared to the non-induced control, the addition of acet-
amide did not inuence the growth of the diﬀerent M. smeg-
matis strains over the 100 hours time period for all
concentrations of acetamide tested (Fig. 2). Importantly, we
were able to monitor the production of GFP in the pYUB1062-of M. smegmatis mc24517 strains. (a) Growth curve of M. smegmatis
urve of M. smegmatis mc24517 transformed with pYUB1062. (d) GFP
Growth curve of M. smegmatismc24517 transformed with pYUB1062-
UB1062-GFP. Concentrations of acetamide induction: red – 0%, green
edia only control.
RSC Adv., 2018, 8, 33087–33095 | 33091
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View Article OnlineGFP M. smegmatis mc24517 expression strain in situ (Fig. 2(f)).
The GFP uorescence increased continually until it reached
a maximum level (corresponding to 13 mg GFP, 100 mL culture),
as detected by uorescence analysis, at approximately 20–30
hours aer induction (Fig. 2(e) and (f)). The high level of
recombinant GFP expression was not detrimental to the growth
of M. smegmatis which is important in the development of
a mycobacterial reporter recombinant protein expression
system (Fig. 2(e)). We did, however, observe that GFP was
expressed at the t ¼ 0 induction time point and that the highest
level of GFP produced were in the absence of acetamide
(Fig. 2(f)), indicating that the promoter is not tightly regulated
and that background expression occurs. In E. coli the T7/lac
promoter is well known to result in leaky expression due to the
negative control of the lac promoter.4,30
To demonstrate that the GFP protein produced from this
expression system can be puried and the purication steps
monitored, we produced GFP in 1 L culture volume. We used
the conditions optimised from our test conditions and grewM.
smegmatis mc24517 transformed with pYUB1062-GFP to an
OD600 of 0.6 and then induced the culture with 0.2% acet-
amide for 20 hours. At this nal 20 hour time point we
measured the GFP uorescence in whole cells which corre-
sponded to the production of 100 mg of GFP. TheM. smegmatis
cell pellets were then lysed by cell disruption and the His6-
tagged GFP protein puried by Ni2+-aﬃnity-chromatography
(IMAC) and the eluted fractions were monitored by in-gel
uorescence and Coomassie blue staining (Fig. 3). Following
purication, we isolated 50 mg of puried GFP protein,
indicating that there is a good correlation between the GFP
that is detected in the whole M. smegmatis cells and the
amount of protein puried. It is likely that incomplete cell
lysis and loss of protein during the purication steps resulted
in the slightly lower yield of puried GFP protein than ex-
pected. It was of interest to note that the yield of puried GFP
obtained from theM. smegmatis expression host is comparable
to the yields of GFP that we have obtained previously from E.
coli. This indicates that the GFP-reporter for protein over-
expression in anM. smegmatis expression system is robust and
comparable to the uorescent based systems that are routinely
used for protein over-expression in E. coli28,29 and S. cerevisiae
hosts.31Fig. 3 Expression and puriﬁcation of GFP in M. smegmatis mc24517. (a)
(b) In-gel ﬂuorescence of the overexpression and puriﬁcation of GFP-H
ﬂow-through, W: buﬀer wash-step, numbers 20–1000 refer to the imid
33092 | RSC Adv., 2018, 8, 33087–33095Production of NagA-GFP-His6 in M. smegmatis mc
24517
To assess the use of the pYUB1062-GFP reporter strain for the
production of mycobacterial proteins for structural and func-
tional studies we chose to produce the mycobacterial N-
acetylglucosamine-6-phosphate (NagA) enzyme as a GFP-fusion.
We have recently produced NagA as His6-tag fused protein in
M. smegmatis mc24517 as soluble protein19 and therefore wanted
to determine whether the GFP-fusion impacted on the expression
yield and/or activity of this protein. To determine the optimal
expression conditions for the NagA-GFP-His6 fusion wemeasured
the OD600 and the GFP uorescence for 24 hours in microtiter
plates following induction at an OD600 of 0.6 with acetamide (0–
0.4%) and observed that the uorescent signal continued to
increase indicating that the NagA-GFP-His6 protein continued to
be produced over this time period (ESI, Fig. S1†). It was inter-
esting to note that the results from this primary screen indicated
that the optimal conditions to produce the NagA-GFP-His6
protein were identical to those used previously to produce His6-
tagged NagA in 1 L culture volume.19 Following cell lysis, the
NagA-GFP-His6 protein was puried by Co
2+-aﬃnity, anion
exchange and size-exclusion chromatography (Fig. 4). The eluted
fractions from each purication step were monitored by analysis
of the uorescence output using a plate-reader and by in-gel
uorescence following SDS-PAGE. The addition of the C-
terminal GFP-tag to the NagA protein enabled the purication
strategy to be optimised and monitored more rapidly compared
to our previous studies with NagA as a His6 fusion.19 The quality
of the protein can be assessed through a comparison of the
intensity of the NagA-GFP-His6 fusion compared to GFP alone
and has been used routinely to monitor the integrity of
membrane proteins expressed as GFP proteins in E. coli.27–29,31–34
Our in-gel uorescence results for the whole cell lysate indicated
a prominent signal at 70 kDa with only low levels of GFP
detected at 27 kDa, indicating that the NagA-GFP-His6 fusion
protein was intact and minimal degradation had occurred
(Fig. 4(a)). The size-exclusion prole indicated that the NagA-GFP-
His6 fusion protein forms a dimer in solution (ESI, Fig. S2†)
which was also observed for the NagA-His6 fusion19 and is char-
acteristic to NagA proteins from other bacterial species.35,36 This
is important and indicates that the oligomeric complex is not
altered by the addition of the C-terminal GFP-tag which has also
been found for proteins expressed as GFP fusions in both E.SDS-PAGE analysis of the overexpression and puriﬁcation of GFP-His6.
is6. M: molecular weight markers in kDa, S: soluble lysate, FT: column
azole concentration in the elution buﬀer (units mM).
This journal is © The Royal Society of Chemistry 2018
Fig. 4 Puriﬁcation of NagA-GFP-His6 expressed in M. smegmatis mc
24517. (a) Elution of NagA-GFP-His6 protein from a Co
2+ column. M:
molecular weightmarkers in kDa, WC: cell lysate, S: soluble lysate, FT: column ﬂow through, NaCl: 1 MNaCl wash, numbers 0 to 1000 refer to the
imidazole concentration in the buﬀer (units mM). (b) QHP anion chromatography of NagA-GFP-His6 following the Co
2+ puriﬁcation step. L:
protein loaded onto the column after the Co2+ puriﬁcation step, FT: column ﬂow through, numbers 100–1000 indicate the NaCl concentrations
in the elution buﬀer (units of mM). (c) Size exclusion chromatography of NagA-GFP-His6. (i) SDS-PAGE stained with Coomassie blue, (ii) cor-
responding in-gel ﬂuorescence analysis and (iii) GFP ﬂuorescence readings following the puriﬁcation steps of NagA-GFP-His6.
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View Article Onlinecoli28,32–34 and S. cerevisiae systems.31 To obtain NagA, the puried
NagA-GFP-His6 fusion was digested with TEV-His6 protease. The
digest went to completion and NagA was obtained by removal of
the digested GFP-His6-tag and the TEV-His6 protease by Ni
2+-Fig. 5 Kinetics of NagA-GFP-His6 before and after cleavage of the GFP-t
the GFP-His6-tag. Each assay was carried out in triplicate and expressed
This journal is © The Royal Society of Chemistry 2018chromatography (ESI, Fig. S3†). Correct folding of the NagA-GFP-
His6 fusion and NagA following cleavage of the GFP-His6-tag was
conrmed by circular-dichroism (ESI, Fig. S4†). The amount of
puried NagA protein that we produced following expression asag. (a) Kinetics of NagA-GFP-His6, (b) kinetics of NagA after cleavage of
as  standard deviation.
RSC Adv., 2018, 8, 33087–33095 | 33093
Table 2 Steady-state kinetic parameters of NagA
Enzyme Fusion-tag GFP-tag Km (mM) kcat (s
1) kcat/Km  103 M 1s1 Reference
NagA His6 Not cleaved 3.2  0.4 91.1  5.5 28.8  3.8 19
NagA GFP-His6 Not cleaved 6.7  1.2 96.4  7.3 14.4  2.8 This study
NagA GFP-His6 Cleaved 6.2  0.6 111.0  4.0 17.9  1.8 This study
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View Article Onlinea GFP fusion (1 mg L1 culture) was comparable to that ob-
tained as a His6 fusion19 (2 mg L1 culture) indicating, impor-
tantly, that the GFP reporter was not detrimental to the
production and purication of the NagA protein.Activity of NagA-GFP-His6
To conrm that production of protein fused with a C-terminal
GFP reporter tag is not detrimental to activity of the protein
we examined the catalytic deacetylation of N-acetylglucosamine-
6-phosphate (GlcNAc6P) substrate by both the NagA-GFP-His6
fusion and the cleaved NagA enzymes using a uorescence
assay.19 The measurements indicated that both NagA-GFP-His6
and NagA were able to deacetylate GlcNAc6P with Km values of
6.7 mM and 6.2 mM and kcat values of 96.4 s
1 and 111 s1
respectively (Fig. 5 and Table 2). Importantly, the kinetic values
that were obtained are comparable to the values previously
obtained for the NagA-His6 fused protein also expressed in M.
smegmatis.19 This indicates that a C-terminal GFP fusion is not
detrimental to the correct folding or catalytic activity of
recombinant proteins expressed in M. smegmatis.Conclusions
In this study we have developed a new method for the eﬃcient
screening and purication of mycobacterial proteins using GFP
and M. smegmatis as a host expression system. Here we have
identied that GFP can be used as a uorescence indicator to
monitor recombinant protein expression in situ in whole M.
smegmatis cells and that it is possible to undertake preliminary
screens in microtiter plate format for the rapid optimisation of
overexpression conditions. The GFP-reporter tag is not detri-
mental to the growth of M. smegmatis and enables the puri-
cation of mycobacterial proteins to be rapidly monitored from
the GFP uorescence detection. The activity of the NagA enzyme
produced as a NagA-GFP-His6 fusion was comparable with the
NagA-His6 fusion indicating that the C-terminal GFP tag does
not aﬀect the biochemical function of the target protein. We
hope that the availability of the pYUB1062-GFP protein
expression system will facilitate the production of Mtb, and
other mycobacterial, proteins and enable new structural and
biochemical insights into this important global pathogen.Conﬂicts of interest
There are no conicts of interest to declare.33094 | RSC Adv., 2018, 8, 33087–33095AbbreviationsXDR-TB Extensively-drug resistant
IMAC Immobilised metal aﬃnity chromatography
Mtb Mycobacterium tuberculosis
GlcNAc6P N-Acetylglucosamine-6-phosphate
NagA N-Acetylglucosamine-6-phosphate deacetylase
OD Optical density
TEV Tobacco etch virus
TB TuberculosisAcknowledgements
The authors would like to thank Professor William R. Jacobs
(Albert Einstein College of Medicine, USA) for providing us with
the pYUB1062 expression vector and the M. smegmatis mc24517
expression system. We would like to thank Dr Debs Brotherton
for providing the His-TEV protease used in these studies. This
work was supported by a Sir Henry Dale Fellowship to EF jointly
funded by the Wellcome Trust and Royal Society (Grant number
104193/Z/14/Z), a grant from the Wellcome Trust (Grant
number 201442/Z/16/Z) and a research grant from the Royal
Society (Grant number RG120405).
References
1 WHO Global Tuberculosis Report, http://www.who.int/tb/
publications/global_report/en/).
2 R. S. Wallis, M. Maeurer, P. Mwaba, J. Chakaya,
R. Rustomjee, G. B. Migliori, B. Marais, M. Schito,
G. Churchyard, S. Swaminathan, M. Hoelscher and
A. Zumla, Lancet Infect. Dis., 2016, 16, e34–46.
3 G. Bashiri and E. N. Baker, Protein Sci., 2015, 24, 1–10.
4 G. L. Rosano and E. A. Ceccarelli, Front Microbiol., 2014, 5,
172.
5 G. Georgiou and P. Valax, Curr. Opin. Biotechnol., 1996, 7,
190–197.
6 R. M. Goldstone, N. J. Moreland, G. Bashiri, E. N. Baker and
J. Shaun Lott, Protein Expression Purif., 2008, 57, 81–87.
7 F. R. Blattner, G. Plunkett 3rd, C. A. Bloch, N. T. Perna,
V. Burland, M. Riley, J. Collado-Vides, J. D. Glasner,
C. K. Rode, G. F. Mayhew, J. Gregor, N. W. Davis,
H. A. Kirkpatrick, M. A. Goeden, D. J. Rose, B. Mau and
Y. Shao, Science, 1997, 277, 1453–1462.
8 S. T. Cole, R. Brosch, J. Parkhill, T. Garnier, C. Churcher,
D. Harris, S. V. Gordon, K. Eiglmeier, S. Gas, C. E. Barry
3rd, F. Tekaia, K. Badcock, D. Basham, D. Brown,
T. Chillingworth, R. Connor, R. Davies, K. Devlin,This journal is © The Royal Society of Chemistry 2018
Paper RSC Advances
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
5 
Se
pt
em
be
r 2
01
8.
 D
ow
nl
oa
de
d 
on
 9
/2
5/
20
18
 3
:1
4:
35
 P
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article OnlineT. Feltwell, S. Gentles, N. Hamlin, S. Holroyd, T. Hornsby,
K. Jagels, A. Krogh, J. McLean, S. Moule, L. Murphy,
K. Oliver, J. Osborne, M. A. Quail, M. A. Rajandream,
J. Rogers, S. Rutter, K. Seeger, J. Skelton, R. Squares,
S. Squares, J. E. Sulston, K. Taylor, S. Whitehead and
B. G. Barrell, Nature, 1998, 393, 537–544.
9 N. A. Lack, A. Kawamura, E. Fullam, N. Laurieri, S. Beard,
A. J. Russell, D. Evangelopoulos, I. Westwood and E. Sim,
Biochem. J., 2009, 418, 369–378.
10 M. Lara, L. Servin-Gonzalez, M. Singh, C. Moreno, I. Cohen,
M. Nimtz and C. Espitia, Appl. Environ. Microbiol., 2004, 70,
679–685.
11 J. Carere, S. E. McKenna, M. S. Kimber and S. Y. Seah,
Biochemistry, 2013, 52, 3502–3511.
12 J. Deng, L. Bi, L. Zhou, S. J. Guo, J. Fleming, H. W. Jiang,
Y. Zhou, J. Gu, Q. Zhong, Z. X. Wang, Z. Liu, R. P. Deng,
J. Gao, T. Chen, W. Li, J. F. Wang, X. Wang, H. Li, F. Ge,
G. Zhu, H. N. Zhang, J. Gu, F. L. Wu, Z. Zhang, D. Wang,
H. Hang, Y. Li, L. Cheng, X. He, S. C. Tao and X. E. Zhang,
Cell Rep., 2014, 9, 2317–2329.
13 F. Bigi, O. Taboga, M. I. Romano, A. Alito, J. C. Fisanotti and
A. A. Cataldi, Braz. J. Med. Biol. Res., 1999, 32, 29–37.
14 https://www.rcsb.org/.
15 J. Neres, F. Pojer, E. Molteni, L. R. Chiarelli, N. Dhar, S. Boy-
Rottger, S. Buroni, E. Fullam, G. Degiacomi, A. P. Lucarelli,
R. J. Read, G. Zanoni, D. E. Edmondson, E. De Rossi,
M. R. Pasca, J. D. McKinney, P. J. Dyson, G. Riccardi,
A. Mattevi, S. T. Cole and C. Binda, Sci. Transl. Med., 2012,
4, 150ra121.
16 S. M. Batt, T. Jabeen, V. Bhowruth, L. Quill, P. A. Lund,
L. Eggeling, L. J. Alderwick, K. Futterer and G. S. Besra,
Proc. Natl. Acad. Sci. U. S. A., 2012, 109, 11354–11359.
17 R. Qamra, S. C. Mande, A. R. Coates and B. Henderson,
Tuberculosis, 2005, 85, 385–394.
18 G. Bashiri, E. F. Perkowski, A. P. Turner, M. E. Feltcher,
M. Braunstein and E. N. Baker, PLoS One, 2012, 7, e45003.
19 M. S. Ahangar, C. M. Furze, C. S. Guy, C. Cooper,
K. S. Maskew, B. Graham, A. D. Cameron and E. Fullam, J.
Biol. Chem., 2018, 293(25), 9770–9783.
20 P. Davanloo, A. H. Rosenberg, J. J. Dunn and F. W. Studier,
Proc. Natl. Acad. Sci. U. S. A., 1984, 81, 2035–2039.This journal is © The Royal Society of Chemistry 201821 F. Wang, P. Jain, G. Gulten, Z. Liu, Y. Feng, K. Ganesula,
A. S. Motiwala, T. R. Ioerger, D. Alland, C. Vilcheze,
W. R. Jacobs Jr and J. C. Sacchettini, Antimicrob. Agents
Chemother., 2010, 54, 3776–3782.
22 E. E. Noens, C. Williams, M. Anandhakrishnan, C. Poulsen,
M. T. Ehebauer and M. Wilmanns, BMC Biotechnol., 2011,
11, 27.
23 M. T. Ehebauer, M. Zimmermann, A. J. Jakobi, E. E. Noens,
D. Laubitz, B. Cichocki, H. Marrakchi, M. A. Laneelle,
M. Daﬀe, C. Sachse, A. Dziembowski, U. Sauer and
M. Wilmanns, PLoS Pathog., 2015, 11, e1004623.
24 S. Daugelat, J. Kowall, J. Mattow, D. Bumann, R. Winter,
R. Hurwitz and S. H. Kaufmann, Microbes Infect., 2003, 5,
1082–1095.
25 C. Poulsen, S. Holton, A. Geerlof, M. Wilmanns and
Y. H. Song, FEBS Lett., 2010, 584, 669–674.
26 G. Bashiri, A. M. Rehan, D. R. Greenwood, J. M. Dickson and
E. N. Baker, PLoS One, 2010, 5, e15803.
27 D. Drew, D. J. Slotboom, G. Friso, T. Reda, P. Genevaux,
M. Rapp, N. M. Meindl-Beinker, W. Lambert, M. Lerch,
D. O. Daley, K. J. Van Wijk, J. Hirst, E. Kunji and J. W. De
Gier, Protein Sci., 2005, 14, 2011–2017.
28 D. E. Drew, G. von Heijne, P. Nordlund and J. W. de Gier,
FEBS Lett., 2001, 507, 220–224.
29 G. S. Waldo, B. M. Standish, J. Berendzen and
T. C. Terwilliger, Nat. Biotechnol., 1999, 17, 691–695.
30 S. K. Kim, D. H. Lee, O. C. Kim, J. F. Kim and S. H. Yoon, ACS
Synth. Biol., 2017, 6, 1766–1773.
31 S. Newstead, H. Kim, G. von Heijne, S. Iwata and D. Drew,
Proc. Natl. Acad. Sci. U. S. A., 2007, 104, 13936–13941.
32 L. E. Bird, H. Rada, A. Verma, R. Gasper, J. Birch,
M. Jennions, J. Lwe, I. Moraes and R. J. Owens, J.
Visualized Exp., 2015, (95), e52357.
33 L. E. Bird, J. E. Nettleship, V. Jarvinen, H. Rada, A. Verma and
R. J. Owens, Adv. Exp. Med. Biol., 2016, 922, 1–11.
34 D. Drew, M. Lerch, E. Kunji, D. J. Slotboom and J. W. de Gier,
Nat. Methods, 2006, 3, 303–313.
35 F. Vincent, D. Yates, E. Garman, G. J. Davies and
J. A. Brannigan, J. Biol. Chem., 2004, 279, 2809–2816.
36 F. M. Ferreira, G. Mendoza-Hernandez, M. Castaneda-
Bueno, R. Aparicio, H. Fischer, M. L. Calcagno and
G. Oliva, J. Mol. Biol., 2006, 359, 308–321.RSC Adv., 2018, 8, 33087–33095 | 33095
